Drug intelligence / Profile preview

SCB01A

Development stage
Phase 1
Lead developer
SynCore Biotechnology
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

SCB01A is a novel small molecule anti-microtubular agent classified as an aroylindole derivative. It acts primarily as a tubulin polymerization inhibitor, disrupting microtubule dynamics within cells. In addition to its direct cytotoxic effects on tumor cells by inhibiting cell division, it exhibits vascular disrupting activity—targeting and damaging the blood vessels that supply tumors. This dual mechanism confers antineoplastic (anticancer) properties. The drug has been evaluated in phase I and II clinical studies for advanced solid tumors and head and neck cancer[1][3][4][5][6][8].

Other names
microtubule inhibitor SCB01Aaroylindole derivative SCB01A
02

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on SCB01A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCB01A.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call